Apotex alleged that particular US court docket judgments and FDA selections discriminated against it, denied it bare minimum normal of therapy and expropriated its expense in pravastatin. Damages sought: US£8 million.condition circumstance being a respondent. On the other hand, US (as well as other) investors have benefited from NAFTA protections.